X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genfit
Deal Size: $107.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 19, 2022
Details:
Data showing both single and repeated intraperitoneal administrations of VS-01 reduced the concentration of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) related to ACLF.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
VS-01 is a potentially lifesaving, multi-organ support therapy that aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins following paracentesis.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Versantis’ lead program, VS-01, is in clinical development as a first-line therapy for the timely reversal of ACLF. VS-01 has received ODD from the EMA and U.S. FDA.
Lead Product(s): VS-01
Therapeutic Area: Genetic Disease Product Name: VS-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
VS-01 is an innovative liposomal-based detoxification therapy that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during liver and kidney failures.
Lead Product(s): VS-01
Therapeutic Area: Genetic Disease Product Name: VS-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
